TABLE 2.

Neutralization profiles with final panel selected (panel 3) for evaluation of samples from clade A, B, C, or D HIV-1 epidemics (n = 463)

VirusCladeOrigin, disease stageCollection yrNeutralization profile with:
Clade B seraMAbs
94UG103AUganda, chronic infection1994Moderately resistantb12 sensitive; 2G12 resistant; 4E10 sensitive
92RW020ARwanda, chronic infection1992Moderately resistantb12 resistant; 2G12 sensitive; 4E10 sensitive
92BR020BBrazil, chronic infection1992Moderately resistantb12 sensitive; 2G12 sensitive; 4E10 borderline resistant
APV13BUnited States, early infection2001Resistantb12 resistant; 2G12 sensitive; 4E10 sensitive
APV17BUnited States, early infection2002Moderately resistantb12 resistant; 2G12 resistant; 4E10 sensitive
APV6BUnited States, early infection2003Sensitiveb12 resistant; 2G12 sensitive; 4E10 sensitive
JR-CSFBUnited States, chronic infection1986Moderately sensitiveb12 sensitive; 2G12 sensitive; 4E10 sensitive
NL4-3BUnited States, chronic infection1985Very sensitiveb12 very sensitive; 2G12 very sensitive; 4E10 very sensitive
93IN905CIndia, chronic infection1993Moderately sensitiveb12 sensitive; 2G12 resistant; 4E10 sensitive
IAVI_C3CAfrica, unknown infection stage2001Moderately sensitiveb12 sensitive; 2G12 resistant; 4E10 sensitive
IAVI_C18CAfrica, unknown infection stage2003Moderately resistantb12 resistant; 2G12 resistant; 4E10 resistant
IAVI_C22CAfrica, unknown infection stage2005Resistantb12 sensitive; 2G12 resistant; 4E10 sensitive
94UG114DUganda, chronic infection1994Moderately resistantb12 resistant; 2G12 resistant; 4E10 sensitive
92TH021CRF01_AEThailand, chronic infection1992Moderately resistantb12 sensitive; 2G12 resistant; 4E10 sensitive
CMU02CRF01_AEThailand, chronic infection1993Moderately resistantb12 sensitive; 2G12 resistant; 4E10 sensitive